Gaurav D. Shah
| Gaurav D. Shah | |
|---|---|
| Born | Dohad, India |
| 🏫 Education | B.A. in Behavioral Neuroscience, Harvard College M.D., Columbia University |
| 💼 Occupation | |
| Known for | Co-founder and CEO of Rocket Pharmaceuticals; Grammy-winning musician |
| 👩 Spouse(s) | Falu |
Gaurav D. Shah, M.D. is an Indo-American physician-scientist, biotechnology executive, and musician. He is a co-founder and chief executive officer of Rocket Pharmaceuticals; a biotechnology company focused on gene therapies for rare genetic diseases.[1][2]
Shah is also a Grammy-nominated singer-songwriter[3][4]
Early life and education
Shah was born in Dohad, India, and raised in Fort Worth, Texas after immigrating to the United States in the 1970s He began studying music at the age of eight.
Shah earned a B.A. in Behavioral Neuroscience from Harvard College, graduating summa cum laude and as a member of Phi Beta Kappa.[5] He earned his M.D. from Columbia University, completed internal medicine training at Brigham & Women's Hospital, and fellowship training in hematology and medical oncology at Memorial Sloan Kettering Cancer Center.[6]
Career
Early career
Shah worked in oncology drug development at ImClone Systems and Eli Lilly and Company.[5] He joined Novartis in 2010, where he held leadership roles in oncology and cell and gene therapy, later serving as Global Program Head for CTL019 (CAR-T).[5]
Rocket Pharmaceuticals
In 2015, Shah co-founded Rocket Pharmaceuticals. The company develops gene therapies for rare diseases using lentiviral and adeno-associated virus (AAV) platforms.[5] The company's Danon disease program reported clinical proof-of-concept for a cardiac gene therapy.[6] In 2024, Fast Company named Rocket one of its most innovative companies.[7] Shah also serves as a board member of Talaris Therapeutics and as chairman of Anjarium Biosciences.[8][9]
Music
Shah plays harmonium, bansuri (flute), and piano. He has performed at Carnegie Hall and Lincoln Center alongside his wife, musician Falu.[6] Shah and Falu were nominated for a Grammy Award for Best Children's Music Album in 2019.[3][4] Their 2023 collaboration "Abundance in Millets" was nominated for a Grammy Award in the Best Global Music Performance category.[3]
Shah often explores the relationship between music, creativity, medicine, and innovation, and has spoken about how music has informed his approach to pattern recognition, scientific curiosity and critcal thinking.[10]
Selected publications
- Phase 1 study of AAV9.LAMP2B gene therapy in Danon disease. The New England Journal of Medicine, 2025.[11]
- Lentiviral gene therapy for severe leukocyte adhesion deficiency type 1. The New England Journal of Medicine, 2025.[12]
- Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma. The Lancet, 2016.[13]
References
- ↑ Albert, Helen (2026-03-27). "Rocket's Therapy for Rare Immunodeficiency Gets Accelerated FDA Approval". Inside Precision Medicine. Retrieved 2026-05-26.
- ↑ Watch, Formulary (2026-05-26). "FDA Issues Complete Response Letter for Kresladi for Rare Immune Disorder | Managed Healthcare Executive". www.managedhealthcareexecutive.com. Retrieved 2026-05-26.
- ↑ 3.0 3.1 3.2 "Gaurav Shah". Grammy.com. Retrieved 2026-05-19.
- ↑ 4.0 4.1 "Falu". Grammy.com. Retrieved 2026-05-19.
- ↑ 5.0 5.1 5.2 5.3 "Gaurav Shah". BioSpace. Retrieved 2026-05-19.
- ↑ 6.0 6.1 6.2 "Gaurav Shah: A Rare Disease Biopharma CEO Shares a Rare Experience". Life Science Leader. Retrieved 2026-05-19.
- ↑ "Rocket Pharmaceuticals: Most Innovative Companies 2024". Fast Company. 2024. Retrieved 2026-05-19.
- ↑ "Talaris Therapeutics Appoints Four Vice Presidents". Business Wire. 2021-02-25. Retrieved 2026-05-19.
- ↑ "Anjarium Biosciences Appoints Gaurav Shah as Chairperson". PR Newswire. 2022-06-22. Retrieved 2026-05-19.
- ↑ Suhrawardi, Rebecca. "Grammy Award Winner, Gaurav Shah, On How He Mastered Music And Medicine". Forbes. Retrieved 2026-05-26.
- ↑ "Phase 1 study of AAV9.LAMP2B gene therapy in Danon disease". The New England Journal of Medicine. 2025. doi:10.1056/NEJMoa2412392.
- ↑ "Lentiviral gene therapy for severe leukocyte adhesion deficiency type 1". The New England Journal of Medicine. 2025. doi:10.1056/NEJMoa2407376.
- ↑ "Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma". The Lancet. 2016. doi:10.1016/S0140-6736(16)30587-6.
External links
This article "Gaurav D. Shah" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Gaurav D. Shah. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
